- 1 Testing the association between tobacco and cannabis use and cognitive functioning:
- Findings from an observational and Mendelian randomization study 2
- Liam Mahedy^{1,2,3} (Ph.D.), Robyn Wootton^{1,2,3} (Ph.D.), Steph Suddell^{1,2,3} (MSc), Caroline 4
- 5 Skirrow^{1,4}, (Ph.D.), Matt Field⁵ (Ph.D.), Jon Heron⁶ (Ph.D.), Matthew Hickman⁶ (Ph.D.),
- 6 Marcus R. Munafò^{1,2,3} (Ph.D.)
- 8 **Affiliations**

7

16

20

23

- 9 ¹School of Psychological Science, University of Bristol, Bristol, UK.
- 10 ²MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK.
- 11 ³National Institute for Health Research Biomedical Research Centre at the University
- 12 Hospitals Bristol NHS Foundation Trust and the University of Bristol, Bristol, UK.
- 13 ⁴Cambridge Cognition, Cambridge, UK.
- 14 ⁵Department of Psychology, University of Sheffield, Sheffield, UK.
- 15 ⁶Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
- 17 Corresponding author: Liam Mahedy, School of Psychological Science, University of Bristol,
- 18 12a Priory Road, Bristol, UK, BS8 1TU.
- 19 Tel: +44 (0) 117 33 10616; Email: liam.mahedy@bristol.ac.uk
- 21 Key words: ALSPAC, cannabis, tobacco, cognition, longitudinal latent class analysis,
- 22 Mendelian randomization.
- 24 World to puratural, 2002s (rewalls chiracy Abstract befriguress, by ables van and affected mass) used to guide clinical practice.

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

Abstract Background: Although studies have examined the association between tobacco and cannabis use in adolescence with subsequent cognitive functioning, study designs are usually not able to distinguish correlation from causation. Methods: First, separate patterns of tobacco and cannabis use were derived using longitudinal latent class analysis based on measures assessed on five occasions from ages 13 to 18 years in a large UK based population cohort (ALSPAC). Cognitive functioning measures comprised working memory, response inhibition, and emotion recognition assessed at 24 years of age. One- and two-sample Mendelian randomization, methods for testing causal inference using genetic variants as proxies for an exposure of interest, were used to examine the causal relationship between smoking initiation/lifetime cannabis use, and subsequent cognitive functioning in ALSPAC. Results: We found evidence of a relationship between tobacco and cannabis use and diminished cognitive functioning for each of the outcomes in the observational analyses. The clearest evidence demonstrated a dose-response relationship between tobacco use and working memory suggesting late-onset regular tobacco smokers (b=-0.29, 95%CI=-0.45 to -0.13), early-onset regular smokers (b=-0.45, 95%CI=-0.84 to -0.05), and early-onset regular cannabis users (b=-0.62, 95%CI=-0.93 to -0.31) performed worse on this task compared to individuals with a very low probability of using tobacco/cannabis. Mendelian randomization analyses were imprecise and did not provide additional support for these results. Conclusions: Overall, there was some evidence to suggest that adolescent tobacco and cannabis use were associated with diminished cognitive functioning. Better powered genetic studies are required to determine whether these associations are causal.

INTRODUCTION

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

Tobacco and cannabis use during adolescence, when the brain is still developing and undergoing considerable structural and function changes (1), is a major public health concern. The association between adolescent tobacco and cannabis use and subsequent cognitive functioning has received particular attention because certain cognitive functions (e.g. working memory, response inhibition, and emotion recognition) do not peak until early adulthood (2–5) in parallel with maturation of the prefrontal cortex (6,7). Due to the prolonged neurodevelopmental period and the potential for the endocannabinoid and nicotinic cholinergic signalling systems to be involved in altering development (8,9), it is plausible that tobacco and cannabis use during this potentially critical period could play a role in disrupting normal brain development (10–13). Nonetheless, there is still uncertainty regarding the nature of the association between tobacco and cannabis use and neurocognitive function. A recent review of prospective studies of the association between cannabis use and cognition in young people (14) highlighted an association between cannabis use and neuropsychological decline (15,16). However, these studies often fail to control for neurocognitive measures prior to cannabis use (17,18) and associations were largely found for the heaviest cannabis users and were often attenuated when potential confounders (e.g. other forms of substance use) were included (16,19). A recent study (20), using a co-twin design (allowing for the disentanglement of shared environmental and genetic factors),

assessed IQ prior to cannabis initiation and found insufficient evidence to suggest cannabis

use was associated with decline in general IQ. Findings from two recent longitudinal studies

of adolescents (21,22) using a repeated measures design suggest that the association

between cognitive functioning and cannabis use could be bidirectional.

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

The direction of association between tobacco and cognitive functioning is also unclear as there is a lack of epidemiological studies that have prospectively examined this relationship. Evidence from animal studies suggests that nicotine exposure may have more deleterious developmental effects during adolescence, when the brain is thought to be more vulnerable (23). Furthermore, human studies suggest that nicotine has a more potent effect when consumed in late adolescence compared to in adulthood (24). One small prospective study (n=112, aged between 17 to 21 years) found that current smokers performed worse than non-smokers on a variety of cognitive assessments including language related IQ and working memory while controlling for earlier cognitive measures and other substance use (25). Finally, one large study (n~20,000) on Israeli male soldiers (26) found a dose-response relationship between number of cigarettes smoked and lower general cognitive ability compared to non-smokers. They also found diminished cognitive functioning in individuals who started starting smoking after 18 years of age. In an effort to strengthen the evidence, we used data from the Avon Longitudinal Study of Parents and Children, a large UK prospective birth cohort, to investigate whether patterns of adolescent tobacco and cannabis use were prospectively associated with cognitive functioning at 24 years of age. As young people do not initiate tobacco or cannabis at the same time (27,28), we used longitudinal latent class analysis (LLCA) to identify heterogenous classes of individuals with different tobacco and cannabis use profiles across adolescence (29). As a next step we used genetic variants that are separately associated with smoking initiation and lifetime cannabis use to perform one- and two-sample Mendelian randomization (MR) to improve causal inference (30). We expected to find that an earlier age of onset and more frequent use (for both substances) would be associated with larger reductions in cognitive function, and that the MR analyses would demonstrate

the hypothesised associations between tobacco and cannabis use and diminished cognitive functioning.

METHODS

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

Observational analyses

Participants and Procedure

The Avon Longitudinal Study of Parents and Children (ALSPAC) is a cohort born in 1991–92. ALSPAC recruited 14,541 pregnant women resident in Avon, UK, with expected dates of delivery between 1 April 1991 and 31 December 1992. The initial number of pregnancies enrolled is 14,541 (for these at least one questionnaire has been returned or a "Children in Focus" clinic had been attended by 19/07/99). Of these initial pregnancies, there was a total of 14,676 foetuses, resulting in 14,062 live births and 13,988 children who were alive at 1 year of age. When the oldest children were approximately 7 years of age, an attempt was made to bolster the initial sample with eligible cases who had failed to join the study originally. The total sample size for analyses using any data collected after the age of 7 years is therefore 15,454 pregnancies, resulting in 15,589 foetuses. Of this total sample 14,901 were alive at 1 year of age (31–33). Of these, 9,997 offspring were invited to attend the 24year clinic assessment. A detailed overview of our study population, including attrition at the different measurement occasions is presented in Supplementary Material Figure S1. Detailed information about ALSPAC is available online www.bris.ac.uk/alspac. A fully searchable data dictionary is available on the study's website http://www.bristol.ac.uk/alspac/researchers/our-data/. Approval for the study was obtained from the ALSPAC Ethics and Law Committee and the Local Research Ethics Committees. Informed consent for the use of data collected via questionnaires and clinics

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

was obtained from participants following recommendations of the ALSPAC Ethics and Law Committee at the time. Consent for biological samples was collected in accordance with the Human Tissue Act (2004). Measures A timeline of data collection is presented in Supplementary Material Figure S2. Exposure variables Information on tobacco and cannabis use were collected on six occasions via questionnaire (Q) or during attendance at a study clinic (C). Median ages at response were: 13y(C), 14y(Q), 15y(C) 16y(Q), 17y(C), and 18y(Q). Tobacco use Patterns of tobacco use have been described in detail elsewhere (34). Responses to one or more questions at each time point were used to derive a repeated four-level ordinal variable with categories 'Non-smoker', 'Occasional smoker' (typically less than once per week), 'Weekly smoker' and 'Daily smoker'. There was good agreement that a four-class solution was adequate in explaining the heterogeneity in tobacco based on model fit criteria (see Table S1a). The four-class model (n=8,525) comprised individuals with a higher probability of 'early-onset regular smokers' (3.4%), 'late-onset regular smokers' (11.6%), 'experimenters' (17.4%), and 'non-smokers' (67.5%) (Figure 1a). Cannabis use Patterns of cannabis use have been described in detail elsewhere (35). Responses to one or more questions at each time point were used to derive a repeated three-level ordinal variable with categories 'Do not use', 'Occasional use' (typically less than once per week) and 'Frequent use' (typically once per week or more). There was good agreement that a four-class solution was adequate in explaining the heterogeneity in cannabis use based on

model fit criteria (see Table S1b). The four-class model (n=8,093) comprised individuals with a higher probability of 'early-onset regular users' (3.6%), 'early-onset occasional users' (2.9%), 'late-onset occasional users' (13.8%), and 'non-users' (79.8%) (Figure 1b).

Outcome variables

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

At 24 years of age (M=24.0 years; SD=9.8 months) participants attended a clinicbased assessment which included computerised cognitive assessments as part of a broader assessment battery of mental and physical health and behaviour. Data collection for the online questionnaires was collected and managed by REDcap electronic data capture tools (36,37). Further information on all three cognitive tasks is presented in Supplementary material.

Working memory

The N-back task (2-back condition) was used to assess working memory. The N-back task (38) is widely used to measure working memory (39-41). A measure of discriminability (d') was chosen as the primary outcome measure given it is an overall performance estimate. High scores on number of hits indicated more accurate identification, while high scores on false alarms indicated less accurate identification. High scores on d', therefore, indicated a greater ability to distinguish signal from noise. d' data were available for n=3,242participants.

Response inhibition

The Stop Signal Task (42) was used to assess response inhibition – the ability to prevent an ongoing motor response. The task consisted of 256 trials, which included a 4:1 ratio of trials without stop signals to trials with stop signals. Mean response times were calculated. An estimate of stop signal reaction time (SSRT) was calculated using the median of the inhibition function approach (43). SSRT used as the primary outcome as it is a reliable

measure of inhibitory control, with shorter reaction times indicating faster inhibition. SSRT data were available for 3,201 participants.

Emotion recognition

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

Emotion recognition was assessed using a six alternative forced choice (6AFC) emotion recognition task (44) comprising of 96 trials (16 for each emotion) which measures the ability to identify emotions in facial expressions that vary in intensity. In each trial, participants were presented with a face displaying one of six emotions: anger, disgust, fear, happiness, sadness, or surprise. Participants were required to select the descriptor that best described the emotion that was present in the face, using the computer mouse. Emotion intensity varied across 8 levels within each emotion from the prototypical emotion to an almost neutral face. Each individual stimulus was presented twice, giving a total of 96 trials. An overall measure of ER (the number of facial emotions accurately identified) was used as the primary outcome. ER data were available for n=3,368 participants.

Potential confounders

Confounders comprised of established risk factors for cognitive functioning that could plausibly have a relationship with earlier substance use. Potential confounders included: income, maternal education, socioeconomic position, housing tenure, sex, and maternal smoking during first trimester in pregnancy. Working memory at approximately 11 years and experience of a head injury/unconsciousness up to 11 years were included to control for cognitive functioning prior to baseline measures of substance use. The inclusion of both measures helps to control for the possibility that the onset of substance use is caused by impaired or lower cognitive performance, thereby allowing for the temporal order between substance use and later cognitive functioning to be established. Finally, a measure of alcohol use asking whether they had ever had a whole drink of alcohol was

collected at age 13 years (up to the first assessment of smoking and cannabis use). Further information is presented in Supplementary material.

Statistical methods

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

Different tobacco and cannabis phenotypes were used across different analytic methods.

Observational analyses

Tobacco and cannabis class membership was related to covariates using the Bolck-Croon-Hagenaars (45) method. This approach uses the weights derived from the latent classes to reflect measurement error in the latent class variable. Linear regression was used to examine the association between the cognitive outcomes and latent class membership controlling for the confounding variables. Results are reported as unstandardized beta coefficients with 95% confidence intervals. Analyses were carried out using Mplus 8.4 (46). Missing data

Missing data was dealt with in three steps. First, full information maximum likelihood (FIML) was used to derive trajectories tobacco (N=8,525) and cannabis (N=8,093) based on individuals who had information on at least one timepoint between 13 and 18 years. For a detailed description of missingness at each timepoint see Tables S2a and S2b. Next, multiple imputation was based on 3,232 participants (for both tobacco and cannabis models) who had information on at least one of the cognitive outcomes. The imputation model (based on 100 datasets) contained performance on all of the cognitive tasks, all measures of tobacco and cannabis use, and potential confounding variables, as well as a number of auxiliary variables known to be related to missingness (e.g., substance use in early adolescence, parental financial difficulties, and other SES variables). Finally, inverse probability weighting was used where estimates of prevalence and associations were

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

weighted to account for probabilities of non-response to attending the clinic. See Table S3 for a detailed description of attrition for completing the cognitive assessments at age 24 years. See Tables S4a and S4b for a detailed description of confounding factors associated with tobacco and cannabis use class membership. Genetic analyses Mendelian randomization (MR) Two-sample MR was used to test the hypothesised causal effect of smoking initiation and lifetime cannabis use on cognitive functioning. The two-sample MR approach requires summary level data from GWAS, enabling SNP-outcome and SNP-exposure effects to be derived from different data sources. As the genetic instrument for smoking we used 378independent genome-wide significant SNPs associated with smoking initiation identified by the GWAS & Sequencing Consortium of Alcohol and Nicotine use (GSCAN https://gscan.sph.umich.edu/) based on a total sample of ~1,200,000 individuals. We used 8-independent genome-wide significant SNPs associated with lifetime cannabis use based on the largest GWAS to date (n=184,765) (47). As outcomes, we used GWAS conducted in ALSPAC $(n\sim2,500)$ for each of our three primary outcome measures: i) working memory assessed using d'; ii) response inhibition assessed using SSRT; and iii) emotion recognition assessed using total number of correctly identified emotions (48). Analyses were performed using the TwoSampleMR R package, part of MR-Base (49). The inverse-variance weighted (IVW) approach was used as a primary analysis, with three complementary estimation methods as sensitivity analyses which each make different assumptions about the nature of horizontal pleiotropy (where the genetic variant associates

with the outcome via an independent pathway to the exposure): MR Egger (50), weighted

median (51), and weighted mode (52). A consistent effect across all of these methods would provide the most confidence that any observed effects are not due to pleiotropy.

Next, one-sample MR analyses using two-stage least squares (2SLS) regression models with robust standard errors was used to examine the full GRS for smoking initiation (378 SNPs) as an instrument for smoking initiation and cannabis use (8 SNPs) as an instrument for lifetime cannabis use in relation to the three cognitive assessments at 24 years of age. Using individual-level data, the first stage involves regressing tobacco/cannabis use upon individual smoking initiation/lifetime cannabis use SNPs. Lifetime tobacco use (n=1,638/5,107) (32%) up to age 15 years and lifetime cannabis use (n=1,348/5,319) (25%) up to age 24 years were chosen as exposures. Each of the cognitive outcomes were then regressed on the fitted values from the stage 1 for tobacco and cannabis use in the second stage. The three key assumptions in MR are 1) the genetic instrument is robustly associated with the exposure of interest; 2) confounders of the exposure-outcome association are not associated with the genetic instrument; and 3) the genetic instrument is not associated with the outcome other than through its association with the exposure; see (30) for a full description. Power calculations conducted for one-sample MR analyses using mRnd (53) indicated that we had 80% power to detect an effect size of 0.24 for smoking initiation and 0.15 for lifetime cannabis use using a sample size of n~3,300 (individuals who had available cognitive data in ALSPAC).

RESULTS

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

- Observational analyses
- 262 Working memory – 2-back task

Unadjusted and adjusted associations between patterns of tobacco/cannabis use from 13 to 18 years and working memory at age 24 are presented in Tables 1a and 1b. There was evidence to suggest that late-onset regular smokers (b=-0.29, 95%CI=-0.45 to -0.13) and earl-onset regular smokers (b=-0.45, 95%Cl=-0.84 to -0.05) showed poorer working memory performance compared to the non-smokers in the fully adjusted model. There was also evidence indicating that early-onset regular cannabis users showed poorer working memory performance compared to the non-cannabis users in the fully adjusted model (b=-0.62, 95%CI=-0.93 to -0.31). In the sensitivity analyses, there was some evidence to suggest that early-onset regular tobacco smoking was associated with fewer correct hits on the N-back task in the fully adjusted models (Table S5a). [Tables 1a and 1b] Response inhibition - stop signal task Unadjusted and adjusted associations between patterns of tobacco/cannabis use from 13 to 18 years and response inhibition at age 24 are presented in Tables 2a and 2b. The fully adjusted models suggest slower SSRT (indicative of impaired response inhibition) in early-onset regular smokers (b=0.18, 95%CI=0.07 to 0.28), and early-onset regular cannabis users (b=0.30, 95%CI=0.08 to 0.52) compared to tobacco and cannabis non-users. All associations were supported by significant Wald test values indicating a significant difference between the groups in terms of their ability to inhibit responses. In the sensitivity analyses, there was evidence to suggest that late-onset regular tobacco and early-onset cannabis users were associated with worse Go and Stop accuracy in the fully adjusted models (Tables S6a and S6b).

[Tables 2a and 2b]

Emotion recognition – 6AFC task

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

Unadjusted and adjusted associations between patterns of tobacco/cannabis use from 13 to 18 years and emotion recognition at age 24 are presented in Tables 3a and 3b. There was evidence to suggest that late-onset regular smokers (b=-0.02, 95%CI=-0.03 to -0.00), and early-onset regular (b=-0.04, 95%CI=-0.08 to -0.01) showed poorer emotion recognition compared to non-smokers in the fully adjusted models. There was insufficient evidence of an association between other patterns of tobacco/cannabis use and emotion recognition. There was some evidence in the sensitivity models to suggest late-onset regular tobacco users had poorer ability to identify 'fear' and 'surprise', while early-onset regular tobacco users had poorer ability to identify 'sad' in the fully adjusted models (Table S7d). Early- and late-onset occasional cannabis users had better ability to identify 'anger' and 'disgust', while late-onset occasional cannabis users had poorer ability to identify 'happy' in the fully adjusted models (Table 8d).

[Tables 3a and 3b]

Genetic analyses

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

Information testing whether the genetic instruments are associated with the confounders are presented in the Supplementary Material (Tables S9a and S9b).

Two-sample Mendelian randomization

Two-sample MR methods provided little evidence to suggest that SNPs associated with smoking initiation were a causal risk factor for deficits in cognitive functioning (Table S4a). Focusing on the IVW estimate as the primary measure, SNPs associated with smoking initiation were not associated with working memory (b=-0.02 95%CI=-0.20 to 0.15; p=0.52); response inhibition (b=-0.06 95%CI=-0.24 to 0.12; p=0.31); or emotion recognition (b=0.00 95%CI=-0.18 to 0.18; p=0.97). Other sensitivity estimates tended to be in the same direction

and failed to demonstrate smoking initiation as a causal risk factor for deficits in cognitive functioning. Similarly, there was little evidence to suggest that SNPs associated with lifetime cannabis use was a causal risk factor for deficits in cognitive functioning (Table S4b). Focusing on the IVW estimate as the primary measure, SNPs associated with lifetime cannabis use were not associated with working memory (b=0.28 95%CI=-0.16 to 0.70; p=0.21); response inhibition (b=-0.13 95%CI=-0.47 to 0.22; p=0.47); or emotion recognition (b=-0.08 95%CI=-0.52 to 0.36; p=0.71). All other sensitivity estimates were in the same direction and failed to demonstrate cannabis use as a causal risk factor for deficits in cognitive functioning. [Tables 4a and 4b] One-sample Mendelian randomization Results from the one-sample MR provided little evidence to suggest that smoking initiation or lifetime cannabis use were causal risk factors for deficits in cognitive functioning (Table 5). SNPs associated with smoking initiation were not associated with working memory (b=0.01 95%CI=-0.06 to 0.29; p=0.21); response inhibition (b=0.16 95%CI=-0.03 to 0.35; p=0.10); or emotion recognition (b=0.00 95%CI=-0.18 to 0.18; p=0.97). Similarly, SNPs

associated with lifetime cannabis use were not associated with working memory (b=-0.37

95%CI=-0.72 to -0.02; p=0.04); response inhibition (b=0.04 95%CI=-0.32 to 0.39; p=0.85); or

330 [Table 5]

emotion recognition (b=-0.08 95%CI=-0.52 to 0.36; p=0.71).

DISCUSSION

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

331

332

This observational study provided evidence to suggest an association between tobacco and cannabis use across adolescence and cognitive functioning at age 24. Lateonset regular smokers and early-onset regular cannabis users had poorer working memory performance, slower ability to inhibit responses, and poorer ability to recognise emotions compared to the non-smokers and non-cannabis users. Our results remained largely consistent when controlling for prior measures of substance use and cognition allowing for clear temporality between exposure and outcomes. Genetic analyses were imprecise and did not provide clear evidence to suggest that smoking initiation and lifetime cannabis use were causally related to cognitive functioning in the ALSPAC sample. It is likely that these analyses were underpowered.

Comparison with previous studies

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

To our knowledge, this is the first study to assess the relationship between tobacco and cannabis use, and subsequent cognitive functioning using a combination of observational and genetic epidemiological approaches. Overall, we found an adverse associations between tobacco/cannabis use and working memory, response inhibition, and emotion recognition in ALSPAC, in that those who initiated use at earlier and later ages, and in those with more frequent use. These findings contribute to a literature of mixed findings regarding the direction of association between tobacco and cannabis exposure and subsequent cognition by suggesting that adolescent tobacco and cannabis use precede observed reductions in cognitive function. These findings support studies that have demonstrated effects may depend on the frequency, duration, and age at onset of use (20,21,54-59).

Our study extends previous findings in a number of ways. First, the observational study was better powered than most of the previous studies as it used data from over 3,200

participants providing information spanning birth to 24 years of age. Second, identifying heterogeneous patterns of tobacco and cannabis use across this crucial period allows individuals who follow markedly different developmental trajectories to be captured (27,28). Third, the cognitive measures were assessed at a time when they are expected to have reached maturity (2-5), in comparison to previous studies which have examined cognitive functioning at earlier ages while they are still maturing. Examining mature levels of cognitive functioning reduces the possibility that cognitive functioning is influencing earlier tobacco and cannabis use, effects that cannot be disentangled in purely cross-sectional studies. Further, our ability to control for earlier measures of cognitive functioning and substance use, prior to the baseline measures of tobacco and cannabis use helps to rule out the possibility of reverse causation. Fourth, our study sought to examine specificity in cognitive functioning, by using well-validated tests to probe different domains of cognitive functioning instead of focusing on general intelligence. Finally, we sought to triangulate our results by using one- and two-sample MR approaches to assess tobacco and cannabis use as causal risk factors for cognitive functioning. This approach can help to overcome the main sources of bias from classical observational approaches, by providing a more reliable estimate of the likely underlying causal relationship.

Limitations

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

There are limitations to this study that should be considered. First, the ALSPAC cohort suffers from attrition, which is higher among the socially disadvantaged (60). We attempted to minimize the effect of drop-out by using multiple imputation, FIML, and inverse probability weighting which assume MAR missing patterns. Although it is not possible to test the MAR assumption, it was made more plausible as a number of SES variables were found to predict whether participants attended the clinic or not (Table S1).

Second, tobacco and cannabis use were self-reported. However, there is evidence to suggest that self-reported assessments are reliable and valid methods (61), and the assessment of tobacco and cannabis use yearly over 6 years in a latent variable framework helps to account for measurement error (62). Third, it is likely that both the one- and twosample MR analyses are underpowered. However, findings using weak instruments tend to bias findings towards the null in the two-sample setting and toward the outcome-risk association in the one-sample setting (63). Finally, it is possible that the direction of the association could work in both ways, that is, impairments in cognitive functioning may precede (and increase the risk of developing) tobacco and cannabis use (21,64-66). We were able to include a number of measures to maximize the robustness of our findings: (i) ascertaining the temporal order of exposures and outcomes; (ii) controlling for premorbid working memory and brain insults prior to measures of tobacco/cannabis use helped to reduce the possibility of cognitive impairments, or lower cognitive abilities in childhood, influencing tobacco/cannabis use; and (iii) it is possible that a common risk factor is influencing both tobacco/cannabis use and lower cognitive function, however MR methods helps to protect against this possibility by minimizing bias from reverse causation and residual confounding.

Implications and conclusions

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

Using a triangulation approach of three separate methods, each with different limitations and potential sources of bias, our study contributes to the understanding of the relationship between adolescent tobacco and cannabis use, and subsequent cognitive functioning. Overall, there was observational evidence that adolescent tobacco and cannabis use were associated with subsequent cognitive functioning, highlighting impairments in a range of cognitive domains, including working memory, response

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

inhibition and emotion recognition. Our findings lend support to the developmental vulnerability hypothesis, in that, tobacco and cannabis use in adolescence, when the brain is undergoing critical development, may have neurotoxic effects. Better powered genetically informed studies are required to determine whether these associations are causal. **Acknowledgements:** We are extremely grateful to all the families who took part in this study, the midwives for their help in recruiting them, and the whole ALSPAC team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists and nurses. The work was undertaken with the support of the MRC and Alcohol Research UK (grant number MR/L022206/1). We acknowledge also support from The Centre for the Development and Evaluation of Complex Interventions for Public Health Improvement (DECIPHer); a UKCRC Public Health Research Centre of Excellence (joint funding (grant number MR/KO232331/1) from the British Heart Foundation, Cancer Research UK, Economic and Social Research Council, Medical Research Council, the Welsh Government and the Wellcome Trust, under the auspices of the UK Clinical Research Collaboration); and the NIHR School of Public Health Research. Support was also provided by the UK Medical Research Council Integrative Epidemiology Unit at the University of Bristol (MM UU 00011/7). LM, RW, SS, and MRM are members of the UK Centre for Tobacco and Alcohol Studies, a UKCRC Public Health Research Centre of Excellence. LM, REW, SS, and MRM are supported by the NIHR Biomedical Research Centre at the University Hospitals Bristol NHS Foundation Trust and the University of Bristol (BRC-1215-20011) and we acknowledge support from NIHR HPRU in Evaluation. The UK Medical Research Council and Wellcome (Grant ref: 102215/2/13/2) and the University of Bristol provide core support for ALSPAC. This publication is the work of the authors and Liam

430

431

432

433

434

435

436

437

438

439

Mahedy and Marcus Munafò will serve as guarantors for the contents of this paper. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health and Social Care. GWAS data were generated by Sample Logistics and Genotyping Facilities at Wellcome Sanger Institute and LabCorp (Laboratory Corporation of America) using support from 23andMe. A comprehensive list of grants funding is available on the ALSPAC website (http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf). Disclosures: CS is employed by Cambridge Cognition. MRM is co-director of Jericoe Ltd, which produces software for the assessment and modification of emotion recognition. LM, RW, SS, MF, JH, & MH report no conflicts of interest.

2008;28(10):2642-50.

440 **REFERENCES** 441 De Bellis MD, Clark DB, Beers SR, Soloff PH, Boring AM, Hall J, et al. Hippocampal 442 volume in adolescent-onset alcohol use disorders. Am J Psychiatry. 2000;157(5):737-443 44. 444 2. Fry AF, Hale S. Relationships among processing speed, working memory, and fluid 445 intelligence in children. Biol Psychol. 2000;54(1-3):1-34. 446 3. Kramer AF, de Sather JCMG, Cassavaugh ND. Development of attentional and 447 oculomotor control. Dev Psychol. 2005;41(5):760-72. Davidson MC, Amso D, Anderson LC, Diamond A. Development of cognitive control 448 4. 449 and executive functions from 4 to 13 years: evidence from manipulations of memory, 450 inhibition, and task switching. Neuropsychologia. 2006;44(11):2037–78. Thomas LA, De Bellis MD, Graham R, LaBar KS. Development of emotional facial 451 5. 452 recognition in late childhood and adolescence. Dev Sci. 2007;10(5):547-58. 453 6. Sowell ER, Delis D, Stiles J, Jernigan TL. Improved memory functioning and frontal 454 lobe maturation between childhood and adolescence: a structural MRI study. J Int Neuropsychol Soc. 2001;7(3):312-22. 455 456 7. Sowell ER, Thompson PM, Holmes CJ, Jernigan TL, Toga AW. In vivo evidence for post-457 adolescent brain maturation in frontal and striatal regions. Nat Neurosci. 1999;2:859. 458 8. Galve-Roperh I, Palazuelos J, Aguado T, Guzman M. The endocannabinoid system and 459 the regulation of neural development: potential implications in psychiatric disorders. 460 Eur Arch Psychiatry Clin Neurosci. 2009;259(7):371-82. 461 9. Newman LA, McGaughy J. Cholinergic deafferentation of prefrontal cortex increases 462 sensitivity to cross-modal distractors during a sustained attention task. J Neurosci.

- 464 10. Jacobus J, Tapert SF. Effects of cannabis on the adolescent brain. Curr Pharm Des.
- 465 2014;20(13):2186–93.
- 466 11. Rubino T, Parolaro D. Long lasting consequences of cannabis exposure in
- 467 adolescence. Mol Cell Endocrinol. 2008;286(1-2 Suppl 1):S108-13.
- 468 12. Slotkin TA. Cholinergic systems in brain development and disruption by
- 469 neurotoxicants: nicotine, environmental tobacco smoke, organophosphates. Toxicol
- 470 Appl Pharmacol. 2004;198(2):132–51.
- 471 13. Dwyer JB, Broide RS, Leslie FM. Nicotine and brain development. Birth Defects Res C
- 472 Embryo Today. 2008;84(1):30–44.
- 473 14. Gonzalez R, Pacheco-Colón I, Duperrouzel JC, Hawes SW. Does cannabis use cause
- declines in neuropsychological functioning? A review of longitudinal studies. J Int
- 475 Neuropsychol Soc. 2017;23(9–10):893–902.
- 476 15. Fried P, Watkinson B, James D, Gray R. Current and former marijuana use: preliminary
- findings of a longitudinal study of effects on IQ in young adults. CMAJ.
- 478 2002;166(7):887–91.
- 479 16. Jackson NJ, Isen JD, Khoddam R, Irons D, Tuvblad C, Iacono WG, et al. Impact of
- adolescent marijuana use on intelligence: Results from two longitudinal twin studies.
- 481 Proc Natl Acad Sci U S A. 2016;113(5):E500-8.
- 482 17. Tait RJ, Mackinnon A, Christensen H. Cannabis use and cognitive function: 8-year
- 483 trajectory in a young adult cohort. Addiction. 2011;106(12):2195–203.
- 484 18. Jacobus J, Squeglia LM, Meruelo AD, Castro N, Brumback T, Giedd JN, et al. Cortical
- 485 thickness in adolescent marijuana and alcohol users: A three-year prospective study
- from adolescence to young adulthood. Dev Cogn Neurosci. 2015;16:101–9.
- 487 19. Mokrysz C, Landy R, Gage SH, Munafò MR, Roiser JP, Curran H V. Are IQ and

perpetuity.

It is made available under a CC-BY 4.0 International license .

educational outcomes in teenagers related to their cannabis use? A prospective 488 489 cohort study. J Psychopharmacol. 2016;30(2):159-68. 490 Meier MH, Caspi A, Danese A, Fisher HL, Houts R, Arseneault L, et al. Associations 20. 491 between adolescent cannabis use and neuropsychological decline: a longitudinal co-492 twin control study. Addiction. 2018;113(2):257-65. 493 Castellanos-Ryan N, Pingault J-B, Parent S, Vitaro F, Tremblay RE, Seguin JR. 21. 494 Adolescent cannabis use, change in neurocognitive function, and high-school 495 graduation: A longitudinal study from early adolescence to young adulthood. Dev Psychopathol. 2017;29(4):1253-66. 496 497 22. Morin J-FG, Afzali MH, Bourque J, Stewart SH, Séguin JR, O'Leary-Barrett M, et al. A 498 population-based analysis of the relationship between substance use and adolescent 499 cognitive development. Am J Psychiatry. 2018;176(2):98-106. 500 23. Slotkin TA. Nicotine and the adolescent brain: insights from an animal model. 501 Neurotoxicol Teratol. 2002;24(3):369-84. 502 24. Azam L, Chen Y, Leslie FM. Developmental regulation of nicotinic acetylcholine 503 receptors within midbrain dopamine neurons. Neuroscience. 2007;144(4):1347-60. 504 25. Fried PA, Watkinson B, Gray R. Neurocognitive consequences of cigarette smoking in 505 young adults--a comparison with pre-drug performance. Neurotoxicol Teratol. 506 2006;28(4):517-25. 507 26. Weiser M, Zarka S, Werbeloff N, Kravitz E, Lubin G. Cognitive test scores in male 508 adolescent cigarette smokers compared to non-smokers: a population-based study. 509 Addiction. 2010;105(2):358-63. 510 27. Chen K, Kandel D. The natural history of drug use from adolescence to the mid-511 thirties in a general population sample. Am J Public Health. 1995;85(1):41–7.

512 28. Degenhardt L, Chiu W-T, Sampson N, Kessler RC, Anthony JC, Angermeyer M, et al. 513 Toward a global view of alcohol, tobacco, cannabis, and cocaine use: findings from 514 the WHO World Mental Health Surveys. PLoS Med. 2008;5(7):e141-e141. 515 Lubke GH, Muthén B. Investigating population heterogeneity with factor mixture 29. 516 models. Psychol Methods. 2005;10(1):21-39. 517 Lawlor D, Richmond R, Warrington N, McMahon G, Davey Smith G, Bowden J, et al. 30. 518 Using Mendelian randomization to determine causal effects of maternal pregnancy 519 (intrauterine) exposures on offspring outcomes: Sources of bias and methods for assessing them. Wellcome open Res. 2017;2:11. 520 521 31. Boyd A, Golding J, Macleod J, Lawlor DA, Fraser A, Henderson J, et al. Cohort Profile: 522 the 'children of the 90s'--the index offspring of the Avon Longitudinal Study of Parents and Children. Int J Epidemiol. 2013;42(1):111-27. 523 524 32. Fraser A, Macdonald-Wallis C, Tilling K, Boyd A, Golding J, Davey Smith G, et al. 525 Cohort Profile: the Avon Longitudinal Study of Parents and Children: ALSPAC mothers cohort. Int J Epidemiol. 2013;42(1):97-110. 526 527 Northstone K, Lewcock M, Groom A, Boyd A, Macleod J, Timpson N, et al. The Avon 33. 528 Longitudinal Study of Parents and Children (ALSPAC): an update on the enrolled 529 sample of index children in 2019. Wellcome Open Res. 2019;4:51. 530 34. Howe LJ, Trela-Larsen L, Taylor M, Heron J, Munafo MR, Taylor AE. Body mass index, 531 body dissatisfaction and adolescent smoking initiation. Drug Alcohol Depend. 2017 532 Sep;178:143-9. Taylor M, Collin SM, Munafo MR, MacLeod J, Hickman M, Heron J. Patterns of 533 35. 534 cannabis use during adolescence and their association with harmful substance use 535 behaviour: findings from a UK birth cohort. J Epidemiol Community Health. 2017

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

Aug;71(8):764-70. 36. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377-81. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, Neal LO, et al. The REDCap 37. consortium: Building an international community of software platform partners. J Biomed Inform. 2019;95(5):103208. 38. Kirchner WK. Age differences in short-term retention of rapidly changing information. J Exp Psychol. 1958;55(4):352-8. 39. Wardle MC, de Wit H, Penton-Voak I, Lewis G, Munafo MR. Lack of association between COMT and working memory in a population-based cohort of healthy young adults. Neuropsychopharmacology. 2013;38(7):1253-63. 40. Rossi R, Zammit S, Button KS, Munafò MR, Lewis G, David AS. Psychotic experiences and working memory: a population-based study using signal-detection analysis. PLoS One. 2016;11(4):e0153148-e0153148. Mahedy L, Field M, Gage S, Hammerton G, Heron J, Hickman M, et al. Alcohol use in 41. adolescence and later working memory: Findings from a large population-based birth cohort. Alcohol Alcohol. 2018;53:251-8. 42. Logan GD, Cowan WB, Davis KA. On the ability to inhibit simple and choice reaction time responses: a model and a method. J Exp Psychol Hum Percept Perform. 1984;10(2):276-91. 43. Band GPH, van der Molen MW, Logan GD. Horse-race model simulations of the stopsignal procedure. Acta Psychol (Amst). 2003;112(2):105-42.

Penton-Voak IS, Bate H, Lewis G, Munafo MR. Effects of emotion perception training 560 44. 561 on mood in undergraduate students: randomised controlled trial. Br J Psychiatry. 562 2012;201(1):71-2. 563 45. Bolck A, Croon M, Hagenaars J. Estimating latent structure models with categorical 564 variables: one-step versus three-step estimators. Polit Anal. 2004;12(1):3–27. 565 Muthén LK, Muthén BO. User's Guide. 7th ed. Muthén LK, Muthén BO, editors. Los 46. 566 Angeles, CA: Muthén & Muthén; 2016. 567 47. Pasman JA, Verweij KJH, Gerring Z, Stringer S, Sanchez-Roige S, Treur JL, et al. GWAS 568 of lifetime cannabis use reveals new risk loci, genetic overlap with psychiatric traits, 569 and a causal influence of schizophrenia. Nat Neurosci. 2018;21(9):1161–70. 570 Mahedy L, Suddell S, Skirrow C, Wootton R, Fernandes GS, Heron J, et al. Alcohol use 48. 571 and cognitive functioning in young adults: an observational and Mendelian 572 randomisation study. medRxiv. 2019;19003327. 573 49. Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. The MR-Base 574 platform supports systematic causal inference across the human phenome. Elife. 2018 May;7. 575 576 Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid 50. 577 instruments: effect estimation and bias detection through Egger regression. Int J 578 Epidemiol. 2015;44(2):512-25. 579 Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent estimation in Mendelian 51. 580 randomization with some invalid instruments using a weighted median estimator. 581 Genet Epidemiol. 2016;40(4):304-14. 52. 582 Hartwig FP, Davey Smith G, Bowden J. Robust inference in summary data Mendelian 583 randomization via the zero modal pleiotropy assumption. Int J Epidemiol.

584 2017;46(6):1985-98. 585 53. Brion M-JA, Shakhbazov K, Visscher PM. Calculating statistical power in Mendelian 586 randomization studies. Int J Epidemiol. 2012;42(5):1497-501. 587 54. Fontes MA, Bolla KI, Cunha PJ, Almeida PP, Jungerman F, Laranjeira RR, et al. 588 Cannabis use before age 15 and subsequent executive functioning. Br J Psychiatry. 589 2011;198(6):442-7. 590 55. Gruber SA, Dahlgren MK, Sagar KA, Gonenc A, Killgore WDS. Age of onset of 591 marijuana use impacts inhibitory processing. Neurosci Lett. 2012;511(2):89-94. 592 56. Mashhoon Y, Betts J, Farmer SL, Lukas SE. Early onset tobacco cigarette smokers 593 exhibit deficits in response inhibition and sustained attention. Drug Alcohol Depend. 594 2018;184:48-56. Goriounova NA, Mansvelder HD. Short- and long-term consequences of nicotine 595 57. 596 exposure during adolescence for prefrontal cortex neuronal network function. Cold 597 Spring Harb Perspect Med. 2012;2(12):a012120-a012120. 598 58. Mokrysz C, Freeman TP, Korkki S, Griffiths K, Curran H V. Are adolescents more 599 vulnerable to the harmful effects of cannabis than adults? A placebo-controlled study 600 in human males. Transl Psychiatry. 2016;6(11):e961-e961. 601 59. Boccio CM, Beaver KM. Examining the influence of adolescent marijuana use on adult 602 intelligence: Further evidence in the causation versus spuriousness debate. Drug 603 Alcohol Depend. 2017;177:199-206. 604 60. Wolke D, Waylen A, Samara M, Steer C, Goodman R, Ford T, et al. Selective drop-out in longitudinal studies and non-biased prediction of behaviour disorders. Br J 605 606 Psychiatry. 2009;195(3):249-56.

Boykan R, Messina CR, Chateau G, Eliscu A, Tolentino J, Goniewicz ML. Self-reported

607

61.

608 use of tobacco, E-cigarettes, and marijuana versus urinary biomarkers. Pediatrics. 609 2019;143(5). 610 62. Bray BC, Lanza ST, Tan X. Eliminating bias in classify-analyze approaches for latent 611 class analysis. Struct Equ Model. 2015;22(1):1-11. 612 63. Davies NM, Holmes M V, Davey Smith G. Reading Mendelian randomisation studies: a 613 guide, glossary, and checklist for clinicians. BMJ. 2018;362:k601. 614 Cousijn J, Wiers RW, Ridderinkhof KR, van den Brink W, Veltman DJ, Goudriaan AE. 64. 615 Effect of baseline cannabis use and working-memory network function on changes in 616 cannabis use in heavy cannabis users: A prospective fMRI study. Hum Brain Mapp. 617 2014;35(5):2470-82. 618 65. Squeglia LM, Jacobus J, Nguyen-Louie TT, Tapert SF. Inhibition during early 619 adolescence predicts alcohol and marijuana use by late adolescence. 620 Neuropsychology. 2014;28(5):782-90. 621 66. Anokhin AP, Golosheykin S. Neural Correlates of Response Inhibition in Adolescents 622 Prospectively Predict Regular Tobacco Smoking. Dev Neuropsychol. 2016;41(1-2):22-623 37.

624




Figure 1a. Distribution of tobacco use across latent classes at each timepoint (n=8,525). Class proportions based on estimated posterior probability₁.

1 Tobacco use at age 13 was omitted from the figure as 'daily smoking' was not recorded at this age. Overall, the 'non-users' reported a low probability of tobacco use across all measurement occasions; 'experimenters' were mostly characterised by smoking on the later measurement occasions only; 'late-onset regular' smokers were mostly characterised by smoking on a daily basis in the later measurement occasions only; while 'early-onset regular' smokers were mostly characterised by smoking on a daily basis across timepoints from age 14 years onwards.




Figure 1b. Distribution of cannabis use across latent classes at each timepoint (n=8,093). Class proportions based on estimated posterior probability₂.

² The 'non users' reported a low probability of cannabis use across all measurement occasions; 'late-onset occasional' cannabis users were mostly characterised by cannabis use on the later measurement occasions only; 'early-onset occasional' cannabis users were mostly characterised by occasional cannabis use across all measurements; while 'regular cannabis users' were mostly characterised by cannabis use across timepoints with increasing involvement from age 15 years onwards.

Table 1a. Smoking patterns from 13 to 18 years and working memory at age 24 (higher d' scores reflect better performance)

	No smoking	Experimenter	Late-onset regular	Early-onset regula	ır
n=3,232 for all models	Reference group	b (95% CI)	b (95% CI)	b (95% CI)	Wald (df) p value
Unadjusted models					
Working memory d'	-	0.01 (-0.10, 0.10)	-0.32 (-0.48, -0.16)	-0.50 (-0.89, -0.10)	28.92 (3) p<0.001
Adjusted for SES					
Working memory d'	-	0.00 (-0.11, 0.11)	-0.28 (-0.44, -0.12)	-0.39 (-0.78, 0.01)	19.78 (3) p<0.001
Adjusted for SES/WM/HI					
Working memory d'	-	0.01 (-0.10, 0.11)	-0.27 (-0.43, -0.11)	-0.42 (-0.81, -0.02)	20.25 (3) p<0.001
Fully adjusted models					
Working memory d'	-	0.01 (-0.12, 0.10)	-0.29 (-0.45, -0.13)	-0.45 (-0.84, -0.05)	22.12 (3) p<0.001

Table 1b. Patterns of cannabis use from 13 to 18 years and working memory at age 24 (lower d' reflect poorer performance)

	Non-user	Late-onset occasional	Early-onset occasional	Early-onset regular	
n=3,232 for all models	Reference group	b (95% CI)	b (95% CI)	b (95% CI)	Wald (df) p value
Unadjusted models					
Working memory d'	-	-0.01 (-0.13, 0.12)	0.24 (-0.05, 0.52)	-0.58 (-0.90, -0.26)	14.10 (3) p=0.003
Adjusted for SES					
Working memory d'	-	-0.06 (-0.18, 0.07)	0.17 (-0.11, 0.45)	-0.60 (-0.91, -0.30)	16.26 (3) p<0.001
Adjusted for SES/WM/HI					
Working memory d'	-	-0.09 (-0.21, 0.04)	0.15 (-0.12, 0.43)	-0.60 (-0.91, -0.30)	17.64 (3) p<0.001
Fully adjusted models					
Working memory d'	-	-0.10 (-0.22, 0.03)	0.12 (-0.17, 0.41)	-0.62 (-0.93, -0.31)	18.56 (3) p<0.001

Table 2a. Smoking patterns from 13 to 18 years and response inhibition at age 24 (shorter reaction times reflect better performance)

	No smoking	Experimenter	Late-onset regular	Early-onset regular	
n=3,232 for all models	Reference group	<i>b</i> (95% CI)	<i>b</i> (95% CI)	b (95% CI)	Wald (df) p value
Unadjusted models					
Stop signal reaction time	-	0.02 (-0.05, 0.09)	0.19 (-0.02, 0.40)	0.21 (0.10, 0.31)	22.73 (3) p<0.001
Adjusted for SES					
Stop signal reaction time	-	0.01 (-0.06, 0.09)	0.08 (-0.13, 0.30)	0.18 (0.07, 0.28)	13.04 (3) p=0.005
Adjusted for SES/WM/HI					
Stop signal reaction time	-	0.01 (-0.06, 0.08)	0.10 (-0.12, 0.32)	0.17 (0.07, 0.27)	13.05 (3) p=0.005
Fully adjusted model					
Stop signal reaction time	-	0.01 (-0.06, 0.09)	0.10 (-0.12, 0.32)	0.18 (0.07, 0.28)	12.78 (3) p=0.005

Table 2b. Patterns of cannabis use from 13 to 18 years and response inhibition at age 24 (longer reaction times reflect poorer performance)

	Non-user	Late-onset occasional	Early-onset occasional	Early-onset regular	
n=3,232 for all models	Reference group	<i>b</i> (95% CI)	b (95% CI)	b (95% CI)	Wald (df) p value
Jnadjusted models					
Stop signal reaction time	-	0.00 (-0.07, 0.08)	0.03 (-0.13, 0.18)	0.29 (0.06, 0.52)	7.02 (3) p=0.07
Adjusted for SES					
stop signal reaction time	-	0.02 (-0.06, 0.10)	0.04 (-0.13, 0.20)	0.30 (0.07, 0.52)	8.03 (3) p=0.04
Adjusted for SES/WM/HI					
stop signal reaction time	-	0.04 (-0.04, 0.11)	0.04 (-0.12, 0.21)	0.30 (0.08, 0.52)	9.25 (3) p=0.02
Fully adjusted model					
Stop signal reaction time	-	0.04 (-0.04, 0.11)	0.05 (-0.11, 0.22)	0.30 (0.08, 0.52)	9.24 (3) p=0.02

Table 3a. Smoking patterns from 13 to 18 and emotion recognition at age 24 (lower scores reflect poorer performance)

	No smoking	Experimenter	Late-onset regular	Early-onset regular	
n=3,232 for all models	Reference group	b (95% CI)	b (95% CI)	<i>b</i> (95% CI)	Wald (df) p value
Unadjusted models					
Total hits	-	0.00 (-0.01, 0.01)	-0.02 (-0.04, -0.01)	-0.05 (-0.08, -0.01)	20.32 (3) p<0.001
Adjusted for SES					
Total hits	-	-0.00 (-0.01, 0.01)	-0.02 (-0.03, -0.00)	-0.04 (-0.07, -0.01)	14.45 (3) p=0.002
Adjusted for SES/WM/HI					
Total hits	-	-0.00 (-0.01, 0.01)	-0.02 (-0.03, -0.00)	-0.04 (-0.08, -0.01)	14.65 (3) p=0.002
Fully adjusted model					
Total hits	-	-0.00 (-0.01, 0.01)	-0.02 (-0.03, -0.00)	-0.04 (-0.08, -0.01)	16.43 (3) p=0.001

Table 3b. Patterns of cannabis use from 13 to 18 and emotion recognition at age 24 (higher scores reflect better performance)

	Non-user	Late-onset occasional	Early-onset occasional	Early-onset regular	
n=3,232 for all models	Reference group	b (95% CI)	b (95% CI)	b (95% CI)	Wald (df) p value
Unadjusted models					
Total hits	-	0.00 (-0.01, 0.02)	0.03 (0.00, 0.06)	-0.03 (-0.06, 0.00)	7.71 (3) p=0.05
Adjusted for SES					
Total hits	-	0.00 (-0.01, 0.01)	0.03 (0.00, 0.05)	-0.02 (-0.05, 0.01)	4.68 (3) p=0.20
Adjusted for SES/WM/HI					
Total hits	-	-0.00 (-0.01, 0.01)	0.03 (-0.00, 0.05)	-0.02 (-0.05, 0.01)	4.50 (3) p=0.21
Fully adjusted model					
Total hits	-	-0.00 (-0.01, 0.01)	0.02 (-0.00, 0.05)	-0.02 (-0.05, 0.01)	4.23 (3) p=0.24

Table S4a. Two-sample MR analyses of the effects of smoking initiation on cognitive functioning (unstandardized coefficients)

Exposure	Outcome	Method	N SNPs	Beta (95% CI)	P-value
Smoking initiation	Working memory	g memory Inverse-Variance Weighted		0.01 (-0.06, 0.29)	0.21
		MR Egger (SIMEX)	341	-0.68 (-1.41, 0.06)	0.07
		Weighted Median	341	0.06 (-0.21, 0.32)	0.65
		Weighted Mode	341	-0.32 (-1.11, 0.48)	0.43
Smoking initiation	Response inhibition	Inverse-Variance Weighted	341	0.16 (-0.03, 0.35)	0.10
		MR Egger (SIMEX)	341	1.30 (-2.22, 0.03)	0.02
		Weighted Median	341	0.21 (-0.07, 0.49)	0.14
		Weighted Mode	341	0.30 (-0.55, 1.16)	0.49
Smoking initiation	Emotion recognition	Inverse-Variance Weighted	341	0.00 (-0.18, 0.18)	0.97
		MR Egger (SIMEX)	341	0.04 (-0.71, 0.79)	0.91
		Weighted Median	341	-0.05 (-0.31, 0.21)	0.68
		Weighted Mode	341	-0.19 (-1.04, 0.67)	0.67

Table S4b. Two-sample MR analyses of the effects of lifetime cannabis use on cognitive functioning (unstandardized coefficients)

Exposure	Outcome	Method	N SNPs	Beta (95% CI)	P-value
Lifetime cannabis use	Working memory	Inverse-Variance Weighted	8	-0.37 (-0.72, -0.02)	0.04
		MR Egger (SIMEX)	8	-0.10 (-0.21, 0.03)	0.17
		Weighted Median	8	-0.38 (-0.81, 0.06)	0.09
		Weighted Mode	8	-0.21 (-0.85, 0.43)	0.55
Lifetime cannabis use	Response inhibition	Inverse-Variance Weighted	8	0.04 (-0.32, 0.39)	0.85
		MR Egger (SIMEX)	8	0.50 (-0.22, 0.02)	0.32
		Weighted Median	8	0.22 (-0.24, 0.68)	0.35
		Weighted Mode	8	0.26 (-0.35, 0.87)	0.43
Lifetime cannabis use	Emotion recognition	Inverse-Variance Weighted	8	-0.08 (-0.52, 0.36)	0.71
		MR Egger (SIMEX)	8	0.06 (-0.22, 0.03)	0.93
		Weighted Median	8	0.02 (-0.46, 0.48)	0.95
		Weighted Mode	8	0.01 (-0.67, 0.69)	0.98
		WCIBIILCU WIOUC	U	0.01 (0.07, 0.03)	0.50

Table 5. One-sample MR analyses of the effects of smoking initiation on cognitive functioning (standardised coefficients)

	β	se	95% CI	р	F statistic
Smoking initiation					
Working memory	-0.38	0.58	-1.51, 0.75	0.51	14.63
Response inhibition	-0.27	0.53	-1.31, 0.77	0.61	18.12
Emotion recognition	-0.53	0.54	-1.59, 0.53	0.33	17.57
Lifetime cannabis use					
Working memory	-1.41	0.97	-3.31, 0.49	0.14	6.70
Response inhibition	0.02	0.68	-1.31, 1.35	0.98	8.87
Emotion recognition	-0.04	0.69	-1.35, 1.27	0.95	8.79